Effects of Sevoflurane and Ketamine on QT in Electroconvulsive Therapy

Ketamine

Brief Summary

The aim of this study was to evaluate the effect of sevoflurane or ketamine on the QTc and Tp-e interval during in patients with major depression.

Intervention / Treatment

  • Drug: Sevoflurane
  • Drug: Ketamine

Condition or Disease

  • Major Depression
  • Electroconvulsive Therapy

Phase

Study Design

Study type: Interventional
Status: Completed
Study results: No Results Available
Age: 18 Years to 60 Years   (Adult)
Enrollment: 24 ()
Funded by: Other

Masking

Clinical Trial Dates

Start date: Feb 12, 2020
Primary Completion: Apr 13, 2020
Completion Date: May 13, 2020
Study First Posted: Jun 06, 2013
Results First Posted: Aug 31, 2020
Last Updated: Jun 06, 2013

Sponsors / Collaborators

Lead Sponsor: N/A
Responsible Party: N/A

Location

Malatya, Turkey

Patients enrolled in the study are randomly allocated by computer-generated random numbers to receive either sevoflurane or ketamine for their initial ECT session. They subsequently receive an alternative study drug in their next session, continuing to alternate between drugs at each session until the sixth session. In group S, sevoflurane are initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus is delivered, In group K, ketamine are given to 1mg/kg ıv bolus.

Electrical stimulus is delivered via bilateral frontotemporal electrodes.The mean arterial pressure (MAP), HR, and ECG are recorded before anesthetic induction (T1), after anesthetic induction (T2) and at 0, 1, 3, 10 min after the seizure ended (T3, T4, T5 and T6, respectively).The QT interval and Tp-e interval are measured by one author, who was unaware of group allocation.

Eligibility Criteria

Sex: All
Minimum Age: 18
Maximum Age: 60

More Details

NCT Number: NCT01870219
Other IDs: Turgut Ozal Medical Center
Study URL: https://ClinicalTrials.gov/show/NCT01870219
Last updated: Jun 17, 2022